

Cavit Boz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7639088/publications.pdf>

Version: 2024-02-01

121
papers

5,681
citations

109321

35
h-index

82547

72
g-index

127
all docs

127
docs citations

127
times ranked

5673
citing authors

#	ARTICLE	IF	CITATIONS
1	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet</i> , The, 2018, 391, 1263-1273.	13.7	684
2	Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. <i>Lancet Neurology</i> , The, 2017, 16, 976-986.	10.2	472
3	Defining secondary progressive multiple sclerosis. <i>Brain</i> , 2016, 139, 2395-2405.	7.6	281
4	Relationship between major depression and heart rate variability.. <i>Psychiatry Research</i> , 2002, 113, 139-149.	3.3	274
5	Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. <i>PLoS ONE</i> , 2012, 7, e48078.	2.5	166
6	Defining reliable disability outcomes in multiple sclerosis. <i>Brain</i> , 2015, 138, 3287-3298.	7.6	162
7	Predictors of long-term disability accrual in relapse-onset multiple sclerosis. <i>Annals of Neurology</i> , 2016, 80, 89-100.	5.3	158
8	Predictors and dynamics of postpartum relapses in women with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 739-746.	3.0	148
9	Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2015, 77, 425-435.	5.3	143
10	Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. <i>Brain</i> , 2013, 136, 3609-3617.	7.6	140
11	Fingolimod after natalizumab and the risk of short-term relapse. <i>Neurology</i> , 2014, 82, 1204-1211.	1.1	138
12	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , The, 2017, 16, 271-281.	10.2	134
13	Status Epilepticus After Stroke. <i>Stroke</i> , 2001, 32, 1169-1172.	2.0	126
14	Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. <i>PLoS ONE</i> , 2015, 10, e0122686.	2.5	122
15	Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1448-1453.	3.0	116
16	Individual risk factors for carpal tunnel syndrome: an evaluation of body mass index, wrist index and hand anthropometric measurements. <i>Clinical Neurology and Neurosurgery</i> , 2004, 106, 294-299.	1.4	107
17	Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. <i>Brain</i> , 2017, 140, 2426-2443.	7.6	94
18	Neuromyelitis Optica in Patients With Myasthenia Gravis Who Underwent Thymectomy. <i>Archives of Neurology</i> , 2006, 63, 851.	4.5	93

#	ARTICLE	IF	CITATIONS
19	Risk of relapse phenotype recurrence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1511-1522.	3.0	73
20	Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.	1.9	71
21	Seasonal variation of relapse rate in multiple sclerosis is latitude dependent. <i>Annals of Neurology</i> , 2014, 76, 880-890.	5.3	67
22	Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsingâ€“remitting multiple sclerosis treated with interferon beta. <i>Clinical Neurology and Neurosurgery</i> , 2006, 108, 124-128.	1.4	60
23	The Impact of Migraine on Epilepsy: A Prospective Prognosis Study. <i>Cephalalgia</i> , 2005, 25, 528-535.	3.9	59
24	The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. <i>Multiple Sclerosis Journal</i> , 2012, 18, 974-982.	3.0	56
25	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1809-1818.	3.0	55
26	Electrodiagnosis of carpal tunnel syndrome in patients with diabetic polyneuropathy. <i>Clinical Neurophysiology</i> , 2011, 122, 1463-1469.	1.5	54
27	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.	1.1	54
28	Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.	3.0	52
29	Ocular and cervical vestibular evoked myogenic potentials in multiple sclerosis patients. <i>Clinical Neurophysiology</i> , 2012, 123, 1872-1879.	1.5	49
30	Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 196-203.	1.9	49
31	Temperament and character profiles of patients with tensionâ€“type headache and migraine. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 536-543.	1.8	48
32	Acute disseminated encephalomyelitis after bee sting. <i>Neurological Sciences</i> , 2003, 23, 313-315.	1.9	45
33	Predictors of disability worsening in clinically isolated syndrome. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 479-491.	3.7	43
34	Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.1	41
35	Reduced effectiveness of long-term interferon-Î² treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study. <i>Multiple Sclerosis Journal</i> , 2007, 13, 1127-1137.	3.0	38
36	Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.	1.1	38

#	ARTICLE	IF	CITATIONS
37	The Kurtzke EDSS rank stability increases 4â€¦years after the onset of multiple sclerosis: results from the MSBase Registry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 305-310.	1.9	37
38	Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 642-652.	3.0	37
39	Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1159-1171.	3.0	36
40	Increasing age at disability milestones among MS patients in the MSBase Registry. <i>Journal of the Neurological Sciences</i> , 2012, 318, 94-99.	0.6	35
41	Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.	2.0	35
42	Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. <i>PLoS ONE</i> , 2012, 7, e38661.	2.5	35
43	The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 520-532.	3.0	34
44	Prognostic indicators in pediatric clinically isolated syndrome. <i>Annals of Neurology</i> , 2017, 81, 729-739.	5.3	34
45	Comparative efficacy of first-line natalizumab vs IFN-Î² or glatiramer acetate in relapsing MS. <i>Neurology: Clinical Practice</i> , 2016, 6, 102-115.	1.6	33
46	<scp>BREMSO</scp>: a simple score to predict early the natural course of multiple sclerosis. <i>European Journal of Neurology</i> , 2015, 22, 981-989.	3.3	32
47	Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.	7.6	32
48	Effect of serotonergic antidepressant therapy on temperament and character scales in patients with chronic tensionâ€“type headache. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 534-542.	1.8	30
49	Contribution of different relapse phenotypes to disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 266-276.	3.0	30
50	Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.	2.0	29
51	VEMP responses are not affected in non-insulin-dependent diabetes mellitus patients with or without polyneuropathy. <i>Acta Oto-Laryngologica</i> , 2008, 128, 768-771.	0.9	28
52	Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e63480.	2.5	26
53	Factors associated with early hospital arrival in acute ischemic stroke patients. <i>Neurological Sciences</i> , 2014, 35, 1567-1572.	1.9	26
54	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.	7.6	24

#	ARTICLE	IF	CITATIONS
55	Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1205-1211.	3.0	23
56	Economic impact of primary headaches in Turkey: a university hospital based study: part II. <i>Journal of Headache and Pain</i> , 2006, 7, 75-82.	6.0	22
57	Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 19, 105-108.	2.0	22
58	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.	0.6	22
59	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.	9.0	21
60	Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. <i>Computer Methods and Programs in Biomedicine</i> , 2021, 208, 106180.	4.7	21
61	Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.	9.0	20
62	The efficacy and safety of dipyron (Novalgin) tablets in the treatment of acute migraine attacks: a double-blind, cross-over, randomized, placebo-controlled, multi-center study. <i>Functional Neurology</i> , 2004, 19, 197-202.	1.3	19
63	Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1346-1357.	3.0	18
64	The Efficacy of Acupuncture in the Treatment of Bell's Palsy Sequelae. <i>JAMS Journal of Acupuncture and Meridian Studies</i> , 2019, 12, 122-130.	0.7	18
65	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. <i>Neurology and Therapy</i> , 2020, 9, 55-66.	3.2	18
66	Benign Acute Childhood Myositis. <i>Medical Principles and Practice</i> , 2004, 13, 227-229.	2.4	15
67	Susac Syndrome: Clinical characteristics, diagnostic findings and treatment in 19 cases. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 94-99.	2.0	15
68	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e869-e880.	1.1	15
69	Evaluation of Plasma Endothelin-1 Levels in Patients with Cerebral Infarction. <i>Angiology</i> , 2002, 53, 77-82.	1.8	14
70	Sertraline versus amitriptyline in the prophylactic therapy of non-depressed chronic tension-type headache patients. <i>Journal of Headache and Pain</i> , 2003, 4, 72-78.	6.0	14
71	Personality Traits of Patients With Multiple Sclerosis and Their Relationship With Clinical Characteristics. <i>Journal of Nervous and Mental Disease</i> , 2014, 202, 408-411.	1.0	13
72	Baclofen is effective in intractable hiccups induced by brainstem lesions. <i>Neurological Sciences</i> , 2001, 22, 409-409.	1.9	12

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------

73	Evaluation of Temperament and Character Features as Risk Factors for Depressive Symptoms in		
----	---	--	--

#	ARTICLE	IF	CITATIONS
91	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009â€“2018. <i>CNS Drugs</i> , 2021, 35, 1097-1106.	5.9	7
92	The COVID-19 from Neurological Overview. <i>Turk Noroloji Dergisi = Turkish Journal of Neurology</i> , 2020, 26, 58-108.	0.3	7
93	Increased plasma endothelin-1 levels in patients with intracerebral hemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2000, 9, 176-180.	1.6	6
94	Transient tic disorder following carbon monoxide poisoning. <i>Journal of Neuroradiology</i> , 2004, 31, 231-233.	1.1	6
95	Cervical vestibular evoked myogenic potentials to air-conducted sound in early amyotrophic lateral sclerosis. <i>Neurophysiologie Clinique</i> , 2012, 42, 119-123.	2.2	6
96	Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.	1.1	6
97	â€“Is RLS a harbinger and consequence of MS?: Striking results of the â€“RELOMS-Tâ€™ studyâ€™. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 42, 102055.	2.0	6
98	Prediction of multiple sclerosis outcomes when switching to ocrelizumab. <i>Multiple Sclerosis Journal</i> , 2022, 28, 958-969.	3.0	6
99	Ocular Myasthenia Gravis Associated With X-Linked Recessive Spinal and Bulbar Muscular Atrophy. <i>Journal of Clinical Neuromuscular Disease</i> , 2004, 5, 115-118.	0.7	5
100	Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2015, 1, 205521731560019.	1.0	5
101	Electrophysiological, functional and histopathological assessments of high dose melatonin on regeneration after blunt sciatic nerve injury. <i>Journal of Clinical Neuroscience</i> , 2020, 72, 370-377.	1.5	5
102	Brain atrophy and lesion burden are associated with disability progression in a multiple sclerosis real-world dataset using only T2-FLAIR: The NeuroSTREAM MSBase study. <i>NeuroImage: Clinical</i> , 2021, 32, 102802.	2.7	5
103	Determinants of disability development in patients with multiple sclerosis. <i>Arquivos De Neuro-Psiquiatria</i> , 2021, 79, 489-496.	0.8	5
104	Magnetic resonance imaging in bilateral brachial neuritis with pure sensory involvement. <i>Neurological Sciences</i> , 2012, 33, 927-930.	1.9	4
105	Comparative analysis of fingolimod versus teriflunomide in relapsingâ€“remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101376.	2.0	4
106	X-linked spinal and bulbar muscular atrophy without proximal atrophy. <i>Clinical Neurology and Neurosurgery</i> , 2002, 105, 14-17.	1.4	3
107	Decreased second to fourth digit ratios in female multiple sclerosis patients. <i>Early Human Development</i> , 2020, 144, 105039.	1.8	3
108	Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.	3.0	3

#	ARTICLE	IF	CITATIONS
109	Isolated hypoglossal nerve palsy in a child. Turkish Journal of Pediatrics, 2004, 46, 101-3.	0.6	3
110	Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. Pharmacoeconomics, 2022, 40, 323-339.	3.3	3
111	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	3.0	2
112	Neuropathic Pain Frequency in Neurology Outpatients: A Multicenter Study. Noropsikiyatri Arsivi, 2021, 58, 257-260.	0.3	1
113	Pregnancy-induced Susac Syndrome: A Case Report. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2018, 2018, 70-71.	0.3	1
114	A 12-month, Open Label, Multicenter Pilot Study Evaluating Fingolimod Treatment in terms of Patient Satisfaction in Relapsing Remitting Multiple Sclerosis Patients - FINE Trial. Noropsikiyatri Arsivi, 2019, 56, 253-257.	0.7	1
115	Evaluating Treatment Decision for Multiple Sclerosis: Involving Patients and Real Life. Noropsikiyatri Arsivi, 2018, 55, S10-S14.	0.3	1
116	Coexistence of restless legs syndrome and multiple sclerosis aggravates anxiety and depression. Arquivos De Neuro-Psiquiatria, 2022, 80, 168-172.	0.8	1
117	A Case Report of Acute Disseminated Encephalomyelitis in a Pregnant Woman After COVID-19 Infection. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2021, 27, 49-51.	0.3	1
118	Matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in multiple sclerosis. Clinical Neurology and Neurosurgery, 2006, 108, 618.	1.4	0
119	Erratum to "Reduced effectiveness of long-term interferon- β treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study" by C Boz, J Oger, E Gibbs, SE Grossberg and the Neurologists of the UBC MS Clinic. Multiple Sclerosis 2007; 13: 1127-1137. Multiple Sclerosis Journal, 2008, 14, 575-575.	3.0	0
120	Reply to: Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]. Multiple Sclerosis and Related Disorders, 2018, 22, 166.	2.0	0
121	Neurological manifestations and etiological risk factors in patients hospitalized with COVID-19 in Turkey. Asian Biomedicine, 2022, 16, 23-30.	0.3	0